<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606033</url>
  </required_header>
  <id_info>
    <org_study_id>IPSY 0905</org_study_id>
    <nct_id>NCT01606033</nct_id>
  </id_info>
  <brief_title>Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating</brief_title>
  <acronym>IPSY</acronym>
  <official_title>Psychological and Emotional Impacts of Participation in Oncologic Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess anxiety/depression and life quality of patients included in
      clinical trials versus patients treated in a standard way.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess anxiety/depression and life quality of patients included in
      clinical trials versus patients treated in a standard way A case-control study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess and compare stress and life quality of patients participating to a clinical trial vs patients treated a standard way</measure>
    <time_frame>4 years</time_frame>
    <description>quality of life questionnaire (QLQ C30) Anxiety and depression questionnaire (HADS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate links between using adjustment therapy and emotional regulation, and emotional and psychological experience of patients facing one or another situation</measure>
    <time_frame>4 years</time_frame>
    <description>adjustment therapy questionnaire (WCC) emotional regulation questionnaire (DERS 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure and compare variation in time of psychological and emotional consequences during treatment</measure>
    <time_frame>5 years</time_frame>
    <description>emotional regulation (DERS 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure the level of knowledge on the implications of participating in a clinical trial (case)</measure>
    <time_frame>5 years</time_frame>
    <description>assess impact of it on psychological and emotional experience</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Metastatic Neoplasm</condition>
  <condition>Recurrent Hematologic Cancer</condition>
  <arm_group>
    <arm_group_label>phase II non randomized study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>phase II non randomized study, &quot;Case&quot; : 40 patients description of patients feeling by questionnaires :
Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey
understanding of the implications of participating in a clinical trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blind randomized phase II or III study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blind randomized phase II or III study: &quot;control&quot; : 40 patients description of patients feeling by questionnaires :
Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey
understanding of the implications of participating in a clinical trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open randomized phase II or III study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey
-understanding of the implications of participating in a clinical trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>receiving standard treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>receiving standard treatment : 120 patients description of patients feeling by questionnaires :
-understanding of the implications of participating in a clinical trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey</description>
    <arm_group_label>phase II non randomized study</arm_group_label>
    <arm_group_label>blind randomized phase II or III study</arm_group_label>
    <arm_group_label>open randomized phase II or III study</arm_group_label>
    <arm_group_label>receiving standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>understanding of the implications of participating in a clinical trial</description>
    <arm_group_label>phase II non randomized study</arm_group_label>
    <arm_group_label>blind randomized phase II or III study</arm_group_label>
    <arm_group_label>open randomized phase II or III study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with solid tumor or recurrent hematologic cancer, treated by chemotherapy or
             targeted therapy evaluated every 2 or 3 cycles; except for clinical trials associating
             non drug treatment (radiotherapy, surgery...)

          -  subject to a 1st, 2nd or 3rd line of antitumor treatment

               -  a phase 2 open labeled study,

               -  a phase 2 or 3 blind randomised study,

               -  a phase 2 or 3 open randomised study,

               -  a standard treatment non participating to a clinical trial

          -  male or female patients ≥ 18 years of age

          -  karnovsky ≥ 70 % or OMS ≤ 2

          -  recovered from prior toxicities

          -  social security covered

          -  written informed consent given

        Exclusion Criteria:

          -  psychiatric disorders, receiving psychotropic treatment

          -  physical or psychological issues

          -  forbidden to be included in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie CLISANT</last_name>
    <role>Study Director</role>
    <affiliation>Oscar Lambret Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oscar Lambret Center</name>
      <address>
        <city>Lille</city>
        <state>Nord Pas de Calais</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul PAPIN Center</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>François Baclesse Center</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHOLET Hospital</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georges-François LECLERC Center</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Léon BERARD Center</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Val D'AURELLE Center</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean GODINOT Institut</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stress</keyword>
  <keyword>Life quality</keyword>
  <keyword>adjustment strategy</keyword>
  <keyword>receiving an antitumor treatment</keyword>
  <keyword>within a clinical trial (case)</keyword>
  <keyword>according to a standard treatment (control)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

